OverviewSuggest Edit

Allakos, a biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The Company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis.
TypePublic
Founded2012
HQRedwood City, US
Websiteallakos.com

Latest Updates

Employees (est.) (Dec 2019)90(+17%)
Job Openings11
Share Price (May 2020)$65 (-6%)

Key People/Management at Allakos

Robert Alexander

Robert Alexander

Chief Executive Officer, Director
Dan Janney

Dan Janney

Chairman
Robert Andreatta

Robert Andreatta

Director
Mark Asbury

Mark Asbury

Chief Legal Officer, General Counsel
Paul Walker

Paul Walker

Director
Simon Greenwood

Simon Greenwood

Chief Business Officer
Show more

Allakos Office Locations

Allakos has an office in Redwood City
Redwood City, US (HQ)
975 Island Dr #201
Show all (1)

Allakos Financials and Metrics

Allakos Revenue

USD

Net income (Q1, 2020)

(27.8m)

EBIT (Q1, 2020)

(29.9m)

Market capitalization (29-May-2020)

3.2b

Closing stock price (29-May-2020)

65.0

Cash (31-Mar-2020)

135.9m

EV

3.0b
Allakos's current market capitalization is $3.2 b.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

General and administrative expense

2.4m3.7m12.4m29.6m

R&D expense

14.7m18.5m33.3m61.9m

Operating expense total

17.1m22.3m45.7m91.4m

EBIT

(17.1m)(22.3m)(45.7m)(91.4m)
Quarterly
USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

General and administrative expense

2.4m3.3m5.8m5.9m7.5m11.6m

R&D expense

7.1m8.7m15.1m14.1m16.1m18.3m

Operating expense total

9.5m12.0m20.9m20.1m23.6m29.9m

EBIT

(9.5m)(12.0m)(20.9m)(20.1m)(23.6m)(29.9m)
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Cash

13.4m85.2m33.7m38.4m

Prepaid Expenses

150.0k1.0m2.7m4.0m

Current Assets

13.6m86.2m181.6m499.9m

PP&E

333.0k445.0k8.8m8.4m
Quarterly
USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Cash

19.3m51.6m31.5m36.5m308.8m135.9m

Prepaid Expenses

3.0m3.6m1.5m1.3m3.1m4.0m

Current Assets

67.1m197.2m168.7m154.3m520.1m483.8m

PP&E

3.4m7.6m9.0m8.7m8.4m8.1m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(17.1m)(23.6m)(43.5m)(85.4m)

Depreciation and Amortization

148.0k241.0k242.0k1.5m

Accounts Payable

(1.1m)510.0k76.0k3.6m

Cash From Operating Activities

(17.6m)(22.6m)(38.4m)(63.0m)
Quarterly
USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Net Income

(17.9m)(29.0m)(20.0m)(39.0m)(60.8m)(27.8m)

Depreciation and Amortization

119.0k183.0k357.0k732.0k393.0k

Accounts Payable

(647.0k)915.0k1.3m874.0k1.7m3.1m

Cash From Operating Activities

(17.4m)(25.8m)(13.3m)(27.7m)(43.9m)(18.6m)
USDY, 2020

EV/EBIT

-101.8 x

EV/CFO

-163.6 x

Financial Leverage

1 x
Show all financial metrics

Allakos Online and Social Media Presence

Embed Graph

Allakos News and Updates

ROSEN, NATIONAL INVESTOR COUNSEL, Files First Securities Class Action Lawsuit Against Allakos Inc. - ALLK

NEW YORK, March 12, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces it is first to file a class action lawsuit on behalf of purchasers of the securities of Allakos Inc. (NASDAQ: ALLK) between August 5, 2019 through December 17, 2019, inclusive (the "Class...

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Allakos (ALLK) Investors with Who Have Suffered Losses to Contact Its Attorneys: Securities Fraud Class Action Filed

SAN FRANCISCO, March 11, 2020 /PRNewswire/ -- Hagens Berman urges Allakos Inc. (NASDAQ: ALLK) investors who have suffered significant losses to submit their losses now. A securities fraud class action has been filed against the Company and certain investors may have valuable claims. Class...

ROSEN, A LEADING LAW FIRM, Continues to Investigate Securities Claims Against Allakos Inc. - ALLK

NEW YORK, Jan. 17, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Allakos Inc. (NASDAQ: ALLK) resulting from allegations that Allakos may have issued materially misleading business...

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Urges Allakos (ALLK) Investors with Significant Losses to Contact Its Attorneys; Firm Investigating Possible Securities Fraud

SAN FRANCISCO, Dec. 19, 2019 /PRNewswire/ -- Hagens Berman urges Allakos Inc. (NASDAQ: ALLK) investors who have suffered significant losses to submit their losses now or contact the firm immediately to learn if they qualify to recover compensable damages. The firm is investigating Allakos...

U.S. biotech firm Allakos exploring options, including sale - Bloomberg

U.S. biotech company Allakos Inc is considering strategic options that include a potential sale, Bloomberg reported on Wednesday, citing people familiar with the matter.

Allakos stock jumps in afternoon trading

Shares of Allakos Inc. rallied 37% in afternoon trading, to a record high. Sources told Bloomberg that the Redwood, Calif.-based biopharmaceutical company, which went public in August, is considering a sale. Allakos is in the early stages of developing treatments for eosinophilic gastritis and alle…
Show more

Allakos Blogs

Allakos Announces the Initiation of Antolimab (AK002) Clinical Studies

Allakos Announces the Initiation of Antolimab (AK002) Clinical Studies Content Import Tue, 03/24/2020 - 16:01 Allakos Announces the Initiation of Antolimab (AK002) Clinical Studies March 24, 2020 at 4:01 PM EDT This release is a backfill from a News Wire …

Allakos Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

Allakos Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update Content Import Tue, 02/25/2020 - 16:02 Allakos Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update February 25, 2020 at 4:01 PM EST …

Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the 2020 AAAAI Annual Meeting

REDWOOD CITY, Calif. , Feb. 24, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell related diseases, today announced that the Company will present clinical and preclinical results

Allakos Reports Third Quarter 2019 Financial Results

REDWOOD CITY, Calif. , Nov. 12, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell related diseases, today reported financial results for the third quarter ended September 30, 2019.

Allakos Announces Multiple Presentations from Its Eosinophilic Gastrointestinal Diseases Program at the American College of Gastroenterology (ACG) 2019 Annual Scientific Meeting

Allakos Announces Multiple Presentations from Its Eosinophilic Gastrointestinal Diseases Program at the American College of Gastroenterology (ACG) 2019 Annual Scientific Meeting Content Import Mon, 10/28/2019 - 09:01 Allakos Announces Multiple Presentations from Its Eosinophilic Gastrointe…

Allakos Reports Second Quarter 2019 Financial Results

Allakos Reports Second Quarter 2019 Financial Results Content Import Mon, 08/05/2019 - 07:15 Allakos Reports Second Quarter 2019 Financial Results August 5, 2019 at 7:15 AM EDT This release is a backfill from a News Wire Earnings REDW…
Show more

Allakos Frequently Asked Questions

  • When was Allakos founded?

    Allakos was founded in 2012.

  • Who are Allakos key executives?

    Allakos's key executives are Robert Alexander, Dan Janney and Robert Andreatta.

  • How many employees does Allakos have?

    Allakos has 90 employees.

  • Who are Allakos competitors?

    Competitors of Allakos include CinCor Pharma, Sosei Heptares and Vyriad.

  • Where is Allakos headquarters?

    Allakos headquarters is located at 975 Island Dr #201, Redwood City.

  • Where are Allakos offices?

    Allakos has an office in Redwood City.

  • How many offices does Allakos have?

    Allakos has 1 office.